Alison M DeDent,Harold R Collard,Neeta Thakur
Alison M DeDent
Rationale: Living in a disadvantaged neighborhood has been associated with worse survival in people with idiopathic pulmonary fibrosis (IPF), however, prior studies have only examined the impact of neighborhood health on outcomes in IPF as ...
OPTIMA: An Open-Label, Noncomparative Pilot Trial of Inhaled Molgramostim in Pulmonary Nontuberculous Mycobacterial Infection [0.03%]
OPTIMA研究：吸入Molgramostim治疗肺非结核分枝杆菌感染的开放性、非比较性试点试验
Rachel M Thomson,Michael R Loebinger,Andrew J Burke et al.
Rachel M Thomson et al.
Rationale: Inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) has been proposed as a potential immunomodulatory treatment for nontuberculous mycobacterial (NTM) infection.Objectives: This open-label, noncomparative pilot tria...
Long-Term Home Noninvasive Ventilation and Exacerbations of Chronic Obstructive Pulmonary Disease: A Real-World Study [0.03%]
长期家庭无创通气对慢性阻塞性肺病急性加重的影响：一项真实世界研究
Jeffrey Marciniuk,Michael Frohlich,Jean Bourbeau et al.
Jeffrey Marciniuk et al.
Sustained Clinical Benefits of Spiration Valve System in Patients with Severe Emphysema: 24-Month Follow-Up of EMPROVE [0.03%]
支气管阀系统治疗重度肺气肿患者的临床获益：EMPROVE研究24个月的随访结果
Gerard J Criner,Jorge M Mallea,Muhanned Abu-Hijleh et al.
Gerard J Criner et al.
Rationale: Follow-up of patients with emphysema treated with endobronchial valves is limited to 3-12 months after treatment in prior reports. To date, no comparative data exist between treatment and control subjects with a longer follow-up....
Randomized Controlled Trial
Annals of the American Thoracic Society. 2024 Feb;21(2):251-260. DOI:10.1513/AnnalsATS.202306-520OC 2024
Racial Differences in 1-Year Mortality after Hospitalization for Chronic Obstructive Pulmonary Disease in the United States [0.03%]
美国慢性阻塞性肺病住院患者的1年死亡率种族差异
Snigdha Jain,Aruna Priya,Penelope Pekow et al.
Snigdha Jain et al.
Rationale: One quarter of Medicare beneficiaries hospitalized for chronic obstructive pulmonary disease (COPD) die within 1 year. Although overall mortality rates are higher among White patients with COPD, racial and ethnic differences in t...
Loop Gain as a Predictor of Blood Pressure Response in Patients Treated for Obstructive Sleep Apnea: Secondary Analysis of a Clinical Trial [0.03%]
基于临床试验的二次分析：增益环路作为阻塞性睡眠呼吸暂停患者血压反应预测因子的研究
Christopher N Schmickl,Jeremy E Orr,Scott A Sands et al.
Christopher N Schmickl et al.
Rationale: Randomized trials have shown inconsistent cardiovascular benefits from obstructive sleep apnea (OSA) therapy. Intermittent hypoxemia can increase both sympathetic nerve activity and loop gain ("ventilatory instability"), which ma...
Impact of Reducing Time-to-Antibiotics on Sepsis Mortality, Antibiotic Use, and Adverse Events [0.03%]
缩短应用抗生素时间对重症监护病房脓毒症患者病死率、抗生素使用及不良事件的影响：一项系统评价和 meta 分析
John P Donnelly,Sarah M Seelye,Patricia Kipnis et al.
John P Donnelly et al.
Rationale: Shorter time-to-antibiotics is lifesaving in sepsis, but programs to hasten antibiotic delivery may increase unnecessary antibiotic use and adverse events. Objectives: We sought to estimate both the benefits and harms of shorteni...
Accelerating Action: Roadmap for the American Thoracic Society to Address Oppression and Health Inequity in Pulmonary and Critical Care Medicine [0.03%]
行动路线图：加速美国胸科协会在肺部和重症医学领域应对压迫和健康不平等的问题
Sande O Okelo,Christopher F Chesley,Isaretta Riley et al.
Sande O Okelo et al.
Racial Differences in Respiratory Impairment, Pneumoconiosis, and Federal Compensation for Western U.S. Indigenous Coal Miners [0.03%]
美国西部土著煤矿工人肺功能障碍、尘肺病和联邦赔偿的种族差异
Jeremy T Hua,Lauren M Zell-Baran,Camille M Moore et al.
Jeremy T Hua et al.
Rationale: Indigenous populations in the United States face numerous health disparities, but the health of Indigenous workers is less well understood. In a recent surveillance study of active Indigenous coal miners, 3% had coal workers' pne...
Risks of Zolpidem among Patients with Chronic Obstructive Pulmonary Disease [0.03%]
慢性阻塞性肺疾病患者使用唑吡坦的风险
Jason M Castaneda,Travis Hee Wai,Laura J Spece et al.
Jason M Castaneda et al.
Rationale: Nonbenzodiazepine benzodiazepine receptor agonists (NBZRA, e.g., zolpidem) are frequently used to treat insomnia among patients with chronic obstructive pulmonary disease (COPD). However, multiple observational studies find that ...